All News

Don’t miss out on the latest pharmacy insights in the Total Pharmacy June issue.

Test your pharmacy news knowledge with our weekly quiz.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

“Retail pharmacy is central to our future and to our overall customer and patient experience. It enables many other things, but it has to change,” said Walgreens CEO Tim Wentworth.

The first-in-class selective dual PDE3 and PDE4 inhibitor from Verona Pharma is the first inhaled product with a novel mechanism of action approved to treat COPD in over 20 years.

At the American Diabetes Association 84th Scientific Sessions, researchers presented findings from 4 studies that investigated the impact of various new diabetes technologies on managing the condition.

Check out this list of our top 10 most read stories from June 2024.

A study found that cannabis use increased the risk of hospitalization and intensive care unit admission following a COVID-19 diagnosis.

Don’t miss out on the latest pharmacy insights in the Drug Topics June issue.

Check out these featured Drug Topics expert interviews from June 2024.

Drug Topics has been on site at McKesson ideaShare this week. Check out this podcast to hear a few of the exciting happenings at this year’s meeting.

The can’t-miss event on July 13 features speakers and CE sessions focused on streamlining pharmacy finances and services.

A study found that having a high level of melanoma knowledge was significantly correlated with having risk factors for the disease, such as skin ultraviolet radiation vulnerability and lighter hair color.

On the second anniversary of the overturning of Roe v Wade, check out recent coverage on abortion and contraceptive access.

Check out these top featured stories from Drug Topics in June 2024.

See what’s trending in pharmacy with a preview of the Total Pharmacy June issue.

In case you missed it, this week we had news about migraine myths, the ongoing bird flu outbreak, improving vaccine hesitancy, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

The strongest independent predictors of becoming adherent to dermatology follow-up included younger age and prior outpatient visits.

Four abstracts presented at ASCO 2024 delved into cannabis and pain management, potential medication interactions, and symptom mitigation, in patients with cancer.

In a webinar conducted by the National Foundation for Infectious Diseases (NFID), experts gathered to publicly address the ongoing bird flu outbreak across many US states.

Check out important updates from the FDA for the week of June 17.

Patrick Alonso, PharmD, CPh, owner and manager of Your Tampa Health Care Advocates, talks about how to build trust with male patients, what health screenings men should be getting, and how pharmacists can help support men’s mental health.

Research presented at ASHP 2024 found that concerns around the safety of COVID-19 vaccines and the credibility of information from public health authorities were the biggest drivers of vaccine hesitancy during the COVID-19 pandemic.

For Migraine and Headache Awareness Month, Drug Topics spoke with Shivang Joshi, MD, MPH, RPh, FAHS to debunk migraine myths and explore resources to promote migraine awareness and education.

Shivang Joshi, MD, MPH, RPh, FAHS discusses how pharmacists can utilize their role as the most accessible health care professional to provide care to patients with migraine, as well as resources to enhance awareness and education.

A poster presented at AHS 2024 found that older patients tended to have more vitamin deficiencies compared to younger patients.

Cefepime/enmetazobactam was granted a 5-year exclusivity extension under GAIN Act legislation.

Shivang Joshi, MD, MPH, RPh, FAHS, headache specialist neurologist at Community Neuroscience Services, debunks common migraine myths.